Santarus, Inc. (NASDAQ:SNTS.DL)

CAPS Rating: No stars

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

2
Player Avatar cvdynasty3 (99.90) Submitted: 12/2/2009 9:49:36 AM : Underperform Start Price: $5.62 SNTS.DL Score: +13.74

FDA will not approve... Inside info boys!!!

Will lose 20-25 pct easily, FDA will need more data

Featured Broker Partners


Advertisement